Zoetis Inc. $ZTS Shares Sold by Midwest Trust Co

Midwest Trust Co reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 6.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,864 shares of the company’s stock after selling 7,151 shares during the period. Midwest Trust Co’s holdings in Zoetis were worth $16,368,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ZTS. Halbert Hargrove Global Advisors LLC grew its stake in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares in the last quarter. NewSquare Capital LLC boosted its holdings in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. Financial Consulate Inc. acquired a new stake in Zoetis during the 3rd quarter valued at approximately $39,000. SJS Investment Consulting Inc. increased its holdings in Zoetis by 1,606.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after purchasing an additional 257 shares during the last quarter. Finally, TruNorth Capital Management LLC acquired a new position in shares of Zoetis in the 3rd quarter valued at approximately $42,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on ZTS shares. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research report on Thursday, December 18th. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Piper Sandler restated a “neutral” rating and issued a $135.00 target price (down previously from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Bank of America downgraded Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target for the company. in a research note on Monday, December 15th. Finally, HSBC set a $140.00 price objective on Zoetis in a report on Wednesday, December 10th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $152.45.

Zoetis Stock Performance

ZTS stock opened at $127.28 on Tuesday. The stock has a market capitalization of $56.09 billion, a price-to-earnings ratio of 21.43, a PEG ratio of 2.20 and a beta of 0.96. The stock’s fifty day moving average is $123.96 and its two-hundred day moving average is $136.01. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.00. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s payout ratio is presently 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.